Last reviewed · How we verify
DA-1241
At a glance
| Generic name | DA-1241 |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH (PHASE2)
- A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM (PHASE1)
- A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-1241 CI brief — competitive landscape report
- DA-1241 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI